USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: AMBERGEN, INC
City: WATERTOWN
State: MA
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $6,269,847.00 31
SBIR Phase II $21,154,214.00 18

Award List:

Self-Organizing Biomolecular Materials as Structural and Patterning Elements for Device Fabrication

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: Dr. Parshuram Rath
Award Amount: $69,990.00

Self-Organizing Biomolecular Materials as Structural and Patterning Elements for Device Fabrication

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency / Branch: DOD / ARMY
Principal Investigator: Dr. Parshuram Rath
Award Amount: $599,093.00
Abstract:
The engineering of materials on a nanometer scale is an important technological goal which would facilitate the development of a new generation of materials and devices. A variety of biological membranes exhibit self-assembly into 2-D arrays including the purple membrane from Halobacteria… More

PHOTOCLEAVABLE TAGS FOR MANIPULATION OF DNA/RNA

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $99,957.00

PHOTOCLEAVABLE REAGENTS FOR ISOLATION OF STEM CELLS

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Olejnik, jerzy
Award Amount: $100,000.00
Abstract:
The isolation of stem cells is a critical technology for the treatment of a wide range of diseases. Since stem cells can proliferate and differentiate, their isolation facilitates transplantation and gene therapies as well as understanding the basic process of hematopoiesis. While progress has been… More

PHOTOCLEAVABLE LINKERS AND MARKERS FOR MASS SPECTROMETRY

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Olejnik, jerzy
Award Amount: $100,000.00

PHOTOCLEAVABLE TAGS FOR MANIPULATION OF DNA/RNA

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $711,578.00

PHOTOCLEAVABLE LINKERS AND MARKERS FOR MASS SPECTROMETRY

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator: Olejnik, jerzy
Award Amount: $749,005.00

NOVEL IN VITRO EXPRESSION METHODS FOR PROTEOME ANALYSIS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $99,993.00
Abstract:
Not Available The rotorcraft industry lacks a validated analysis tool that would enable designers to use composite bonded joints in primary structures. The overall goal of this program is to develop such a tool by combining state-of-the-art analysis methods with an extensive test database in order… More

NOVEL TECHNOLOGY FOR THE ANALYSIS OF GENE EXPRESSION

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $161,291.00
Abstract:
Not Available The next generation of amphibious assault vehicles will be capable of carrying 18 marines at a water speed of 25 kts and a ground speed of 45 mph, a significant improvement over current vehicles. Unfortunately, however, there is the potential for extremely high noise levels inside the… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jerzy Olejnik
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Jerzy Olejnik
Award Amount: $372,701.00

Novel In Vitro Expression Methods for Proteome Analysis

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $0.00
Abstract:
DESCRIPTION (Applicant's abstract): Proteomic analysis is an important goal for the post-genomic era. While all genes in the human genome have now been decoded, the function of most of these genes remains undetermined. A new approach for proteomic analysis was… More

Novel Technology for the Analysis of Gene Expression

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $0.00
Abstract:
DESCRIPTION: (provided by applicant) The goal of this project is to develop a new technology for the rapid screening and analysis of cancer-linked proteins. AmberGen has made significant progress during Phase I by… More

Novel Technology for the Analysis of Gene Expression

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $549,192.00
Abstract:
DESCRIPTION: (provided by applicant) The goal of this project is to develop a new technology for the rapid screening and analysis of cancer-linked proteins. AmberGen has made significant progress during Phase I by… More

Novel In Vitro Expression Methods for Proteome Analysis

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $388,410.00
Abstract:
DESCRIPTION (Applicant's abstract): Proteomic analysis is an important goal for the post-genomic era. While all genes in the human genome have now been decoded, the function of most of these genes remains undetermined. A new approach for proteomic analysis was… More

Cell-Free Protein Labeling for Drug Discovery

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $98,440.00
Abstract:
DESCRIPTION (Applicant's abstract): The completion of the human genome project has opened a new chapter in drug discovery. In contrast to conventional methods, where a drug library is screened against a single protein, the entire proteome is now available for screening.… More

FLUORESCENT PROTEIN TARGETS FOR CE-LIF DRUG SCREENING

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jerzy Olejnik
Award Amount: $99,989.00
Abstract:
More rapid and economical methods of drug +____________________________________ screening are sought by the pharmaceutical industry due to the dramatic projected increase in the number of "druggable" targets. This project aims to develop such a method based on the use of novel tRNA-based… More

TRNA LABELING OF CELLULAR EXPRESSED PROTEINS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark J. Lim
Award Amount: $99,889.00
Abstract:
The completion of the human genome project highlights a need for high-throughput analysis of gene expression at the protein level. Proteomics involves global analysis of the entire expressed complement of the genome. The general aim of this project is to introduce a powerful method for labeling… More

PROTEOME ARRAY FOR GLOBAL MAPPING OF CELLULAR PATHWAYS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jerzy Olejnik
Award Amount: $599,682.00
Abstract:
DESCRIPTION (provided by applicant): Based on recent progress in sequencing the human genome, a new goal has emerged: to express and analyze the human proteome. The development of proteome arrays will accelerate progress in several key areas of biology and medicine including mapping cellular… More

Novel Microarray System for In Vitro Allergen Testing

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jerzy Olejnik
Award Amount: $599,468.00
Abstract:
DESCRIPTION (provided by applicant): Fifty million Americans suffer from allergic diseases including asthma, rhinitis, sinusitis, dermatitis and food allergy. Allergies constitute the 6th leading cause of chronic disease and involve at least $20 billion in annual health care costs. For type I… More

Cell Free Protein Labeling with Molecular Partners

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jerzy Olejnik
Award Amount: $99,969.00
Abstract:
DESCRIPTION (provided by applicant): Cell free protein expression labeling provides a means for incorporation of fluorescent markers (fluorotags) and affinity tags (affytags) into proteins which can be used for a variety of biotechnological applications including proteomics and drug discovery.… More

Molecular Test for Inherited Mutations in Breast Cancer

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $186,970.00
Abstract:
DESCRIPTION (provided by applicant): Breast cancer is the most common malignancy, which occurs in women and the 2nd leading cause of cancer death. While the majority of breast cancers are sporadic (not inherited), approximately 10 percent are due to inherited mutations in the BRCA1 and BRCA2… More

Photocleavable ICAT Reagents for Quantitative Proteomics

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jerzy Olejnik
Award Amount: $99,992.00
Abstract:
DESCRIPTION (provided by applicant): Proteomics is set to have a profound impact on disease diagnosis, treatment and monitoring. Protein expression profiling is one of the important parameters that can be monitored in the course of neoplastic disease. While several fast and efficient proteomic tools… More

Mass Spectrometric Detection of Drug-Resistant HIV

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $599,854.00
Abstract:
DESCRIPTION (provided by applicant): There are approximately one million persons in the U.S. infected with HIV-1, with 40,000 new cases reported each year. While most of these patients greatly benefit from highly active antiretroviral therapy (HAART), they often develop multi-drug resistance… More

Cell-Free Protein Labeling for Drug Discovery

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): The human genome has opened a new chapter for drug discovery. In contrast to conventional drug discovery methods, which screen a drug library against a single protein target, the entire protein complement of the genome, i.e. the proteome, is now available for… More

Cell-Free Protein Labeling for Drug Discovery

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $749,938.00
Abstract:
DESCRIPTION (provided by applicant): The human genome has opened a new chapter for drug discovery. In contrast to conventional drug discovery methods, which screen a drug library against a single protein target, the entire protein complement of the genome, i.e. the proteome, is now available for… More

Microarray Assay for Detection of Lab Animal Pathogens

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jerzy Olejnik
Award Amount: $121,713.00
Abstract:
DESCRIPTION (provided by applicant): The main goal of this project is to develop a microarray based system for comprehensive health assessment of laboratory animals. This microarray based test would be capable of simultaneous testing for the presence of all relevant pathogens and would require only… More

ADVANCED TECHNOLOGY FOR ASSAYING CANCER-DRUG RESISTANCE

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark J. Lim
Award Amount: $183,926.00
Abstract:
DESCRIPTION (provided by applicant): Significant advances have been made in the development of a new generation of molecularly targeted cancer drugs, many of which are only now emerging from the drug development pipeline. Examples of small molecule drugs are imatinib (Gleevec), used to treat CML,… More

High Sensitivity Molecular Test for Colorectal Cancer

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $187,250.00
Abstract:
DESCRIPTION (provided by applicant): There exists an urgent need to develop an effective, non-invasive method of detecting colorectal cancer (CRC), the second leading cause of cancer deaths in the U.S. Such non-invasive testing, if instituted for a large segment of the population, could result in… More

Advanced Molecular Diagnostic Test for Neurofibromatosis

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $150,000.00
Abstract:
DESCRIPTION (provided by applicant): Neurofibromatosis (NF) is an autosomal dominant disorder caused by mutations in the NF1 and NF2 genes. Currently, more than 100,000 Americans suffer from NF type 1 (NF1) which has one of the highest prevalence rates for a genetic disease (1/3,500 births). NF1 is… More

Molecular Test for Inherited Mutations in Breast Cancer

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $1,389,627.00
Abstract:
ESCRIPTION (provided by applicant): Breast cancer is the most common malignancy which occurs in women and the second leading cause of cancer death. While the majority of breast cancers are sporadic (e.g. not inherited), approximately 10% are due to inherited mutations in the BRCA1 and BRCA2 genes… More

Photocleavable ICAT Reagents for Quantitative Proteomics

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Mark Lim
Award Amount: $749,000.00
Abstract:
DESCRIPTION (provided by applicant): Protein expression profiling is becoming one of the most attractive tools for monitoring the course of neoplastic disease as well as identifying diagnostic biomarkers associated with the disease. While several proteomic tools have been extensively investigated… More

Microarray Assay for Detection of Lab Animal Pathogens

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Rajiv Pande
Award Amount: $749,830.00
Abstract:
DESCRIPTION (provided by applicant): Research animals play a crucial role in biomedical research, drug development and toxicology testing. It is estimated that an average population of over 30 million mice and rats is maintained in the U.S. alone for these purposes. The presence of undetected… More

Novel Methods for Molecular Analysis of Colorectal Polyps

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $187,062.00
Abstract:
DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States. Considerable evidence has shown that cancer fatalities can be dramatically reduced through early detection and removal of premalignant adenomatous polyps by… More

A Novel-Invasive CRC Test Based on Mass Spec of In Vitro Expressed Proteins

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sadanand Gite
Award Amount: $154,247.00
Abstract:
DESCRIPTION (provided by applicant): There exists an urgent need to develop an effective, non-invasive method for large-scale colorectal cancer (CRC) screening, the second leading cause of cancer deaths in the U.S. Such non-invasive testing, if instituted for a large segment of the population, could… More

Novel Proteomic Arrays of In Vitro Expressed Proteins for Autoimmune Disease

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Mark Lim
Award Amount: $1,972,749.00
Abstract:
DESCRIPTION (provided by applicant): Progress in sequencing the human genome has led to a new goal - expressing and characterizing the human proteome. A promising area where proteomics can have a major impact is autoimmune disease. Proteome-wide screening against sera from patients with particular… More

Mass Spectrometric Detection of Drug-Resistant HIV

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: James Han
Award Amount: $2,546,731.00
Abstract:
DESCRIPTION (provided by applicant): There are an estimated one million people in the U.S. infected with HIV-1, with 40,000 new cases reported each year. While most of these patients greatly benefit from highly active anti-retroviral therapy (HAART), they often develop multi-drug resistance… More

Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: James Han
Award Amount: $1,180,532.00
Abstract:
DESCRIPTION (provided by applicant): There exists an urgent need to develop an effective, non-invasive method of detecting colorectal cancer (CRC), the second leading cause of cancer deaths in the U.S. Such non-invasive testing, if instituted for a large s egment of the population, could result in a… More

Advanced Molecular Diagnostic Test for Neurofibromatosis

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Mark Lim
Award Amount: $1,150,044.00
Abstract:
DESCRIPTION (provided by applicant): Advanced Molecular Diagnostic Test for Neurofibromatosis ABSTRACT Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder caused by mutations in the NF1 gene. In children, NF1 causes learning disabilities, coor dination problems and benign tumors later… More

ADVANCED TECHNOLOGY FOR ASSAYING CANCER-DRUG RESISTANCE

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Mark Lim
Award Amount: $1,259,949.00
Abstract:
DESCRIPTION (provided by applicant): Significant advances have been made toward the development of a new generation of molecularly targeted cancer drugs, many of which are only now emerging from the pipeline. This project aims to develop a new, highly sens itive technology for detecting… More

A New Approach for the Non-Invasive Detection of Bladder Cancer

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Christopher Sears
Award Amount: $187,175.00
Abstract:
DESCRIPTION (provided by applicant): There is an urgent need to develop an effective method for detection of primary and recurrent bladder cancer. Bladder cancer is the fourth most common malignancy in men and the ninth most common malignancy in women in W estern countries. If identified early,… More

Novel Methods for Molecular Analysis of Colorectal Cancer Tissue

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: James Han
Award Amount: $1,573,641.00
Abstract:
DESCRIPTION (provided by applicant): A key rationale of this project is the growing need for an improved low-cost, high sensitivity multigene mutation profiling method for tumors. An important example is the recent recommendation of the National Comprehens ive Cancer Network (NCCN) to screen all… More

Proteome Bead-Display for Discovery of Tumor Antigens

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark Lim
Award Amount: $188,151.00
Abstract:
DESCRIPTION (provided by applicant): A promising area of cancer research is the discovery of cancer specific tumor-associated antigens (TAA). Screening the sera of patients having particular cancers against proteomic libraries, to detect autoantibody bindi ng, can lead to the discovery of panels of… More

Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Christopher Sears
Award Amount: $2,998,830.00
Abstract:
DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is the second leading cause of cancer deaths in the U.S and Western world. Despite  increased screening and advances in treatment, the mortality rate (~50,000/year) and high national health-care  burden for CRC is likely to… More

Global Proteomic Screening by MALDI Spectrometric Imaging of Protein-Bead Arrays

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark Lim – 617-923-9930
Award Amount: $299,730.00
Abstract:
DESCRIPTION (provided by applicant): Sequencing of the human genome has led to a new and even more ambitious goal - characterization of the human proteome. Such an endeavor involves not only understanding the function of hundreds of thousands of differentproteins expressed in human cells but also… More

Proteome Bead-Display for Discovery of Tumor Antigens

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Mark Lim – 617-923-9930
Award Amount: $1,463,364.00
Abstract:
DESCRIPTION (provided by applicant): There is an urgent need for early-detection cancer biomarkers which can significantly lower the high mortality and cost of treating cancer. One of the most promising candidates for such biomarkers is tumor-associated autoantigens (TAA), autoantibodies to which… More

Multiplexed Bead-based In Vitro Pediatric Allergy Test

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark Lim – 617-923-9930
Award Amount: $596,918.00
Abstract:
DESCRIPTION (provided by applicant): This proposal focuses on the development of a high-throughput, high sensitivity, low blood-volume, multiplex system for in vitro diagnosis of pediatri food allergies. Allergies comprise a group of immune disorders constituting the 6th leading cause of chronic… More

Photocleavable Bead Technology for Glycomics

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mark Lim – 617-923-9930
Award Amount: $698,424.00
Abstract:
DESCRIPTION: Post-translational modifications of proteins (PTMs) play a central role in diverse cellular processes including protein folding, targeting, signal transduction, immune response, adherence, motility and protein degradation. Over 300 differenttypes of PTMs are already known and are… More

IGF::OT::IGF OTHER FUNCTIONS PHASE I, TOPIC 309, LABEL-FREE MULTIVARIATE CANCER DIAGNOSIS

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Christopher Sears – 617-923-9990
Award Amount: $199,767.00
Abstract:
Significant progress has been made recently in developing multi-analyte prognostic cancer signatures based on gene expression profiling (GEP). However, current industry-standard RT-PCR platforms require substantial amounts of clinical samples, such as multiple FFPE tumor sections. These large sample… More